Comparison of MEOPA + Paracetamol Versus Morphine Treatment in Acute Coronary Syndrome Analgesia.
Launched by UNIVERSITY HOSPITAL, TOULOUSE · Jul 22, 2014
Trial Information
Current as of October 02, 2025
Completed
Keywords
ClinConnect Summary
The investigators wish to compare the use of morphine according to current recommendations with the use of MEOPA associated with intravenous paracetamol in the management of patients with STEMI. The investigators hypothesize that the association of MEOPA and paracetamol, which is easy to use in a pre-hospital setting, will give patients pain relief as effectively as morphine.
This alternative treatment would avoid the use of morphine, whose potentially damaging consequences on myocardial function have been suggested by experimental studies and by an observational study. The physician of th...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient with STEMI \< 12 h treated before hospital admission and pain ≥ 4 on the numerical rating scale.
- Exclusion Criteria:
- • Acute severe hemodynamic, respiratory or neurological failure
- • Heart failure: Killip class III and IV
- • Known allergy to morphine or nitrous oxide
- • Patient who has already received morphine or MEOPA before the arrival of the hospital team during the 4 hours preceding the pre-hospital intervention
- • Contraindications to nitrous oxide
- • Patient unable to assess pain intensity on the numerical rating scale
- • Patient under legal guardianship
- • Pregnancy
- • Patient transported by air ambulance
About University Hospital, Toulouse
The University Hospital of Toulouse is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, the hospital integrates cutting-edge scientific inquiry with comprehensive clinical services. Its multidisciplinary team of healthcare professionals collaborates with renowned researchers to facilitate pioneering studies across various medical fields, aiming to enhance treatment options and improve patient outcomes. As a prominent institution in the region, the University Hospital of Toulouse is committed to fostering an environment of excellence in both education and research within the healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nancy, France
Nantes, France
Poitiers, France
Tours, France
Lille, France
Toulouse, France
Limoges, France
Marseille, France
Bobigny, France
Pontoise, France
Bordeaux, France
Valence, France
Montpellier, France
Corbeil Essonnes, France
Contamine Sur Arve, France
Chateauroux, France
Chartres, France
Clermont Ferrand, France
Agen, France
Besançon, France
Bourg En Bresse, France
Chambéry, France
Clichy, France
Dijon, France
Foix, France
Garches, France
Grenoble, France
La Roche Sur Yon, France
Lyon, France
Melun, France
Metz, France
Nice, France
Paris, France
Paris, France
Paris, France
Pringy, France
Saint Gaudens, France
Toulon, France
Vienne, France
Saint Denis, Réunion
Patients applied
Trial Officials
Sandrine Charpentier, PH,MD
Principal Investigator
CHU Toulouse
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials